Πέμπτη 14 Ιουλίου 2022

“Inhaled Zanamivir versus Oral Oseltamivir to Prevent Influenza-related Hospitalization or Death: A Nationwide Population-based Quasi-experimental Study”

alexandrossfakianakis shared this article with you from Inoreader
to the editor—In their recent article, Su et al compared the effectiveness of inhaled zanamivir and oral oseltamivir for influenza patients in a quasi-experimental cohort study using population-based National Health Insurance Research Database [1]. They found that prescribing zanamivir for clinically diagnosed influenza patients within 48 hours was not inferior to oseltamivir in terms of the risk of subsequent influenza-related hospitalization and death. In addition to the limitations mentioned by the authors, we would like to share some ideas regarding the study design as well as further investigations that would be of interest to the readers.
View on Web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου